Chymase inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3065-3071

  Yahiro, Eiji ^a   Miura, Shin ichiro ^a,b   Imaizumi, Satoshi ^a   Uehara, Yoshinari ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin II type; Angiotensin II forming pathways; Local renin angiotensin system; Receptor blockers

Indexed keywords

4 [1 [[BIS (4 METHYLPHENYL)METHYL]CARBOMOYL] 3 (2 ETHOXYBENZYL)4 OXOOAZETIDINE 2 YLOXYL]BENZOIC ACID; [3 (3 AMINO 4 CARBOXY)PHENYLSULFONYL] 7 CHLOROQUINAZOLINE 2,4(1H,3H) DIONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; RAMIPRIL; SUN 13834; SUNC 8257; TEIE 548; TEIF 00806; TY 51469; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD FLOW; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DIASTOLIC HEART FAILURE; HEART ATRIUM FIBRILLATION; HEART HYPERTROPHY; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; INFLAMMATORY INFILTRATE; LIPID STORAGE; MAST CELL; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHYLOGENY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SPECIES DIFFERENCE;

ACETAMIDES; ANIMALS; ATRIAL FIBRILLATION; AZETIDINES; BENZOATES; CARDIOVASCULAR DISEASES; CHYMASES; HEART FAILURE; HUMANS; HYPERTENSION; MAST CELLS; OXAZOLES; PYRIMIDINES; QUINAZOLINES; SULFONAMIDES;

EID: 84878644649     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170014     Document Type: Article

References (81)

1. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-90.
2. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin IIforming enzyme in the human heart. J Biol Chem 1990; 265: 22348-57.
3. Takai S, Jin D, Miyazaki M. New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci 2010; 113: 301-9.
4. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci 1996; 58: 591-7.
5. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M. Characterization of chymase from human vascular tissues. Clin Chim Acta 1997; 265: 13-20.
6. Chandrasekharan UM, Sanker S, Glynias MJ, Karnik SS, Husain A. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science 1996; 271: 502-5.
7. Guo C, Ju H, Leung D, Massaeli H, Shi M, Rabinovitch M. A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J Clin Invest 2001; 107: 703-15.
8. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha-and beta-chymases. Biochim Biophys Acta 2000; 1480: 245-57.
9. Le Trong H, Neurath H, Woodbury RG. Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci USA 1987; 84: 364-7.
10. Sanker S, Chandrasekharan UM, Wilk D, Glynias MJ, Karnik SS, Husain A. Distinct multisite synergistic interactions determine substrate specificities of human chymase and rat chymase-1 for angiotensin II formation and degradation. J Biol Chem 1997; 272: 2963-8.
11. Powell JS, Clozel JP, Müller RK, et al. Inhibitors of angiotensinconverting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8.
12. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, Steinberg MI. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci 1991; 49: PL223-8.
13. Miyazaki M, Wada T, Shiota N, Takai S. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens 1999; 13(Suppl 1): S21-5.
14. Takai S, Sakonjo H, Fukuda K, et al. A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[,4-dioxo-1-phenyl-7-(2-pyridyloxy)]2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther 2003; 304: 841-4.
15. Hayward CS, Kelly RP, Collins P. The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 2000; 46: 28-49.
16. Chancey AL, Gardner JD, Murray DB, Brower GL, Janicki JS. Modulation of cardiac mast cell-mediated extracellular matrix degradation by estrogen. Am J Physiol Heart Circ Physiol 2005; 289: H316-21.
17. Harnish DC, Albert LM, Leathurby Y, et al. Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2004; 286: G118-25.
18. Knight PA, Wright SH, Lawrence CE, Paterson YY, Miller HR. Delayed expulsion of the nematode Trichinella spiralis in mice lacking the mucosal mast cell-specific granule chymase, mouse mast cell protease-1. J Exp Med 2000; 192: 1849-56.
19. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of promatrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280: 9291-6.
20. Abonia JP, Friend DS, Austen WG Jr, et al. Mast cell protease 5 mediates ischemia-reperfusion injury of mouse skeletal muscle. J Immunol 2005; 174: 7285-91.
21. Kunori Y, Koizumi M, Masegi T, et al. Rodent alpha-chymases are elastase-like proteases. Eur J Biochem 2002; 269: 5921-30.
22. Andersson MK, Karlson U, Hellman L. The extended cleavage specificity of the rodent betachymases rMCP-1 and mMCP-4 reveal major functional similarities to the human mast cell chymase. Mol Immunol 2008; 45: 766-75.
23. Andersson MK, Enoksson M, Gallwitz M, Hellman L. The extended substrate specificity of the human mast cell chymase reveals a serine protease with well-defined substrate recognition profile. Int Immunol 2009; 21: 95-104.
24. Tchougounova E, Pejler G, Abrink M. The chymase, mouse mast cell protease 4, constitutes the major chymotrypsin-like activity in peritoneum and ear tissue: a role for mouse mast cell protease 4 in thrombin regulation and fibronectin turnover. J Exp Med 2003; 198: 423-31.
25. Vyas H, Krishnaswamy G. Paul Ehrlich's "Mastzellen"--from aniline dyes to DNA chip arrays: a historical review of developments in mast cell research. Methods Mol Biol 2006; 315: 3-11.
26. Krishnaswamy G, Ajitawi O, Chi DS. The human mast cell: an overview. Methods Mol Biol 2006; 315: 13-34.
27. Constantinides P. Mast cells and susceptibility to experimental atherosclerosis. Science 1953; 117: 505-6.
28. Cairns A, Constantinides P. Mast cells in human atherosclerosis. Science 1954; 120: 31-2.
29. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995; 92: 1084-8.
30. Kaartinen M, PentillaÅN A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669-78.
31. Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978; 52: 447-52.
32. Hara M, Ono K, Hwang MW, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 2002; 195: 375-81.
33. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399-405.
34. Tsuruda T, Kato J, Hatakeyama K, et al. Adrenomedullin in mast cells of abdominal aortic aneurysm. Cardiovasc Res 2006; 70: 158-64.
35. Balakumar P, Arora MK, Ganti SS, Reddy J, Singh M. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol Res 2009; 60: 24-32.
36. Balakumar P, Reddy J, Singh M. Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy? Mol Cell Biochem 2009; 330: 187-92.
37. Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009; 15: 940-5.
38. Li M, Liu K, Michalicek J, et al. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J Clin Invest 2004; 114: 112-20.
39. Judström I, Jukkola H, Metso J, et al. Mast cell-dependent proteolytic modification of HDL particles during anaphylactic shock in the mouse reduces their ability to induce cholesterol efflux from macrophage foam cells ex vivo. Atherosclerosis 2010; 208: 148-54.
40. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells upregulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-97.
41. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481-90.
42. Berger RM. Possibilities and impossibilities in the evaluation of pulmonary vascular disease in congenital heart defects. Eur Heart J 2000; 21: 17-27.
43. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-63.
44. Bartelds B, van Loon RL, Mohaupt S, et al. Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. Chest. 2012; 141: 651-60.
45. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297: 1689-92.
46. McNeil HP, Shin K, Campbell IK, et al. The mouse mast cellrestricted tetramer-forming tryptases mouse mast cell protease 6 and mouse mast cell protease 7 are critical mediators in inflammatory arthritis. Arthritis Rheum 2008; 58: 2338-46.
47. Magnusson SE, Pejler G, Kleinau S, Abrink M. Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis. FASEB J 2009; 23: 875-82.
48. Waern I, Jonasson S, Hjoberg J, et al. Mouse mast cell protease 4 is the major chymase in murine airways and has a protective role in allergic airway inflammation. J Immunol 2009; 183: 6369-76.
49. Balzar S, Chu HW, Strand M, Wenzel S. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am J Respir Crit Care Med 2005; 171: 431-9.
50. Oleksyszyn J, Powers JC. Irreversible inhibition of serine proteases by peptide derivatives of (alpha-aminoalkyl)phosphonate diphenyl esters. Biochemistry 1991; 30: 485-93.
51. Takai S, Jin D, Sakaguchi M, Kirimura K, Miyazaki M. An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Jpn J Pharmacol 2001; 86: 124-6.
52. Fukami H, Imajo S, Ito A, et al. Substituted 3-phenylsulfonylquinazoline-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase. Drug Des Discov 2000; 17: 69-84.
53. Takai S, Jin D, Nishimoto M, et al. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 2001; 69: 1725-32.
54. Hoshino F, Urata H, Inoue Y, et al. Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 2003; 41(Suppl 1): S11-8.
55. Masaki H, Mizuno Y, Tatui A, et al. Structure-activity relationship of benzo[b]thiophene-2-sulfonamide derivatives as novel human chymase inhibitors. Bioorg Med Chem Lett 2003; 13: 4085-8.
56. Muramatsu M, Yamada M, Takai S, Miyazaki M. Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensindependent pathway in hamster sponge granulomas. Br J Pharmacol 2002; 137: 554-60.
57. Uehara Y, Urata H, Ideishi M, Arakawa K, Saku K. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res 2002; 55: 870-6.
58. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003; 107: 2555-8.
59. Inoue N, Muramatsu M, Jin D, et al. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis 2009; 204: 359-64.
60. Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther 2011; 339: 143-51.
61. Takai S, Jin D, Ohzu M, Tanaka K, Miyazaki M. Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocin-induced diabetes. J Pharmacol Sci 2009; 110: 459-65.
62. Gumprecht J, Zychma M, Grzeszczak W, et al. Angiotensin Iconverting enzyme and chymase gene polymorphisms-relationship to left ventricular mass in type 2 diabetes patients. Med Sci Monit 2002; 8: CR603-6.
63. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14: 1738-47.
64. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymasedependent angiotensin II-generating pathway in diabetic complications. Circulation 2006; 113: 1353-60.
65. Maeda Y, Inoguchi T, Takei R, et al. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol 2010; 299: F1328-38.
66. Nishimoto M, Takai S, Fukumoto H, et al. Increased local angiotensin II formation in aneurismal aorta. Life Sci 2002; 71: 2195-205.
67. Thompson RW, Holmes DR, Mertens RA, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysminfiltrating macrophages. J Clin Invest. 1995; 96: 318-26.
68. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995; 15: 1145-51.
69. Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007; 117: 3359-68.
70. Sun J, Zhang J, Lindholt JS, et al. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 2009; 120: 973-82.
71. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21: 53-7.
72. Pat B, Chen Y, Killingsworth C, et al. Chymase inhibition prevents fibronectin and myofibrillar loss and improves cardiomyocyte function and LV torsion angle in dogs with isolated mitral regurgitation. Circulation 2010; 122: 1488-95.
73. Jin D, Takai S, Sakaguchi M, Okamoto Y, Muramatsu M, Miyazaki M. An antiarrhythmic effect of a chymase inhibitor after myocardial infarction. J Pharmacol Exp Ther 2004; 309: 490-7.
74. Jin D, Takai S, Yamada M, et al. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res 2003; 60: 413-20.
75. Wei CC, Hase N, Inoue Y, et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 2010; 120: 1229-39.
76. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006; 114: e257-354.
77. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial Fibrillation Pathophysiology: Implications for Management. Circulation 2011; 124: 2264-74.
78. Liao CH, Akazawa H, Tamagawa M, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 2010; 120: 242-53.
79. Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res 2007; 101:455-64.
80. Cristovam PC, Arnoni CP, de Andrade MC, et al. ACE-and chymase-dependent angiotensin II generation in normal and glucosestimulated human mesangial cells. Exp Biol Med 2008; 233: 1035-43.
81. Singh R, Leehey DJ. Effect of ACE inhibitors on angiotensin II in rat mesangial cells cultured in high glucose. Biochem Biophys Res Commun 2007; 357: 1040-5.